title: [Vonoprazan: a novel potassium-competitive acid blocker].
abstract: A potent, rapid acting potassium-competitive acid blocker, vonoprazan, is introduced for clinical use in Japan. A number of phase III clinical trials comparing the efficacy of vonoprazan with lansoprazole, showed non-inferior or superior effectiveness in a spectrum of acid-related diseases. In particular, vonoprazan was superior to regular dose of lansoprazole in healing severe gastroesophageal reflux diseases (Los Angeles grade C and D). A triple therapy regimen with vonoprazan, amoxicillin and clarithromycin for 7 days also showed an excellent eradication rate exceeding 90%. The adverse events across these trials were comparable with the standard dose of lansoprazole. As a consequence of profound acid suppression, serum gastrin during vonoprazan therapy rose to much higher levels than those during lansoprazole therapy, pointing to a requirement for the assurance of long-term safety of vonoprazan.
authors.forename: Kentaro
authors.initials: K
authors.lastname: Sugano
mesh_terms: D002986:Clinical Trials as Topic; D005744:Gastric Acid / Q000378:metabolism; D005764:Gastroesophageal Reflux / Q000188:drug therapy; D006801:Humans; D026902:Potassium Channel Blockers / Q000737:chemistry / Q000627:therapeutic use*; D054328:Proton Pump Inhibitors / Q000627:therapeutic use; D011758:Pyrroles / Q000737:chemistry / Q000627:therapeutic use*; D013449:Sulfonamides / Q000737:chemistry / Q000627:therapeutic use*
chemical_list: C552956:1-(5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl)-N-methylmethanamine; D026902:Potassium Channel Blockers; D054328:Proton Pump Inhibitors; D011758:Pyrroles; D013449:Sulfonamides